Share on StockTwits

Research analysts at Empire Asset Management initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report released on Tuesday. The firm set a “sell” rating and a $6.00 price target on the stock. Empire Asset Management’s target price indicates a potential downside of 56.40% from the company’s current price.

Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) traded up 2.54% during mid-day trading on Tuesday, hitting $14.11. 616,717 shares of the company’s stock traded hands. Vanda Pharmaceuticals has a one year low of $5.70 and a one year high of $19.25. The stock’s 50-day moving average is $11.97 and its 200-day moving average is $13.06. The company’s market cap is $477.9 million.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its earnings data on Thursday, May 8th. The company reported ($0.79) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.29) by $0.50. The company had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.50 million. During the same quarter in the prior year, the company posted ($0.15) earnings per share. The company’s quarterly revenue was up 12.3% on a year-over-year basis. On average, analysts predict that Vanda Pharmaceuticals will post $-2.22 earnings per share for the current fiscal year.

Vanda Pharmaceuticals Inc (NASDAQ:VNDA) is a biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.